Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Celltex To Initiate New Clinical Program As It Responds To FDA Letter 

 
October 1, 2012 - (The Sacramento Bee) - "Celltex Therapeutics Corp. announced today that it has received a letter, dated Sept. 24, 2012, from the U.S. Food and Drug Administration. The letter stated the agency's opinion that the process Celltex uses to multiply adult stem cells is subject to FDA regulation as biological drug manufacturing."  Read Full Article

 

Posted on 8-Oct-12 by Gallerno, Jacob
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: